Biopath Ventures
Venture Capital
Active
Millbrae, United States
1
5M
1
1
- Areas of investment
Summary
The company was established in Asia in Singapore. The main department of described VC is located in the Singapore.
For fund there is a match between the location of its establishment and the land of its numerous investments - Singapore. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight One BioMed. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical.
The usual cause for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Seeds Capital, ARCH Venture Partners.
The top activity for fund was in 2019. Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
Investor highlights
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 1
- Investments by industry
- Medical (1)
- Biotechnology (1)
- Investments by region
-
- Singapore (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 5
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| One BioMed | 10 Jul 2019 | Biotechnology, Medical | Early Stage Venture | 5M | Singapore, Central |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.